We are live on ! Find out more
XFOR icon

X4 Pharmaceuticals

62 hedge funds and large institutions have $108M invested in X4 Pharmaceuticals in 2021 Q2 according to their latest regulatory filings, with 19 funds opening new positions, 8 increasing their positions, 18 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

12% more first-time investments, than exits

New positions opened: 19 | Existing positions closed: 17

3% more funds holding

Funds holding: 6062 (+2)

0% more funds holding in top 10

Funds holding in top 10: 33 (0)

0.86% less ownership

Funds ownership: 3.09%2.23% (-0.86%)

22% less capital invested

Capital invested by funds: $139M → $108M (-$30.9M)

56% less repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 18

Holders
62
Holders Change
+2
Holders Change %
+3.33%
% of All Funds
1.08%
Holding in Top 10
3
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.05%
New
19
Increased
8
Reduced
18
Closed
17
Calls
$167K
Puts
Net Calls
+$167K
Net Calls Change
+$167K
Name Holding Trade Value Shares
Change
Change in
Stake
AIP
76
Ameritas Investment Partners
Nebraska
-$8K -33 Closed
Bank of Montreal
77
Bank of Montreal
Ontario, Canada
-$5K -16 Closed
GWS
78
Glassman Wealth Services
Virginia
-$3K -10 Closed
Simplex Trading
79
Simplex Trading
Illinois
+$503 +2 New

XFOR Hedge Fund Activity: Q2 2021 in Review

62 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in X4 Pharmaceuticals (XFOR) for Q2 2021, worth a combined $108M — down 22% from $139M a quarter earlier.

Buyers outnumbered sellers: 19 funds opened new XFOR positions and 17 closed out — a net gain of 2 holders — while 8 added to existing stakes and 18 trimmed.

The largest buyer was AIGH Capital Management, opening a new position worth an estimated $12.1M. The largest seller was BlackRock, cutting an estimated $6.94M.

  • 62 institutional investors held X4 Pharmaceuticals (XFOR) as of Q2 2021, up from 60 in Q1 2021.
  • Funds reported $108M of X4 Pharmaceuticals stock for Q2 2021, down 22% quarter-over-quarter.
  • 19 funds opened new X4 Pharmaceuticals positions in Q2 2021 and 17 closed out, a net change of +2 holders.
  • The largest X4 Pharmaceuticals buyer in Q2 2021 was AIGH Capital Management, an estimated $12.1M added.
  • The largest X4 Pharmaceuticals seller in Q2 2021 was BlackRock, an estimated $6.94M sold.

Based on aggregated 13F filings for Q2 2021.